https://doi.org/10.4081/monaldi.2026.4027
Clinical course management and outcomes of tubercular empyema. A prospective study in a high tuberculosis area of Pakistan
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Accepted: 6 October 2026
Published: 27 October 2026
Mycobacterium tuberculosis (MTB) rarely causes purulent empyema compared to other bacterial pathogens. This study aimed to determine the clinical course, radiological findings, pleural fluid characteristics, surgical interventions, complications, and outcomes of tubercular empyema. This cohort study was conducted in the Department of Pulmonology at Ayub Teaching Hospital, Abbottabad, Pakistan, from July 2023 to January 20, 2026. Different types of empyema were compared using normally distributed continuous variables (age, total leukocyte count, and protein levels) through one-way analysis of variance. Homogeneity of variances was assessed using Levene’s test. Tukey’s post hoc test was applied when variances were equal, while the Games–Howell test was used when this assumption was violated. Associations between clinical variables and empyema types were further evaluated using Binary logistic regression. Results were reported as odds ratios with 95% confidence intervals. A p-value <0.05 was considered statistically significant. A total of 38 patients were included over 2.7 years. Of these, 53% (n=20) were male and 47% (n=18) were female. Most patients (78%) were from Khyber Pakhtunkhwa, 11% were from other provinces (Islamabad and Karachi), and 11% were from Afghanistan. The mean age was 46±18 years (range: 14-75 years). Nearly all male patients were engaged in high-risk occupations such as mining, hotel labor, driving, or teaching. Tubercular empyema was observed in 58% (n=22) of patients, and bacterial empyema in 42% (n=16). The most common presenting symptoms were cough, fever, and shortness of breath (67%). Chest pain was present in 50% of patients with bacterial empyema. Thick, calcified pleura (67%) was the most common radiological feature in tubercular empyema, followed by hilar lymphadenopathy. Pleural fluid analysis showed positivity rates of 33% for acid-fast bacilli, 44% for tuberculosis culture, and 56% for GeneXpert. Additionally, 33% of tubercular empyema cases were diagnosed via Abram’s pleural biopsy. Tubercular empyema demonstrates distinct clinical, radiological, and pleural fluid characteristics. Although associated with significant complications, outcomes can be improved with timely diagnosis and appropriate management. The neutrophilic effusion doesn’t exclude a workup for pleural tuberculosis.
Downloads
WHO- WHO consolidated guidelines on tuberculosis. Module 3: diagnosis. 2025. Available from https://www.who.int/publications/i/item/9789240116924
National Institutes of Health. National Tuberculosis Control Program of Pakistan. Available from: https://www.nih.org.pk/national-tb-control-program.
Koh WJ. Progression of tuberculous pleurisy: from a lymphocyte-predominant free-flowing effusion to a neutrophil-predominant loculated effusion. Tuberc Respir Dis 2016;80:90-2. DOI: https://doi.org/10.4046/trd.2017.80.1.90
Light RW. Update on tuberculous pleural effusion. Respirology 2010;15:451-8. DOI: https://doi.org/10.1111/j.1440-1843.2010.01723.x
Choi H, Chon HR, Kim K, et al. Clinical and laboratory differences between lymphocyte-and neutrophil-predominant pleural tuberculosis. PLoS One 2016;11:e0165428. DOI: https://doi.org/10.1371/journal.pone.0165428
Bielsa S, Palma R, Pardina M, et al. Comparison of polymorphonuclear-and lymphocyte-rich tuberculous pleural effusions. Int J Tuberc Lung Dis 2012;17:85-9. DOI: https://doi.org/10.5588/ijtld.12.0236
Porcel JM. Tuberculous pleural effusion. Lung 2009;187:263-70. DOI: https://doi.org/10.1007/s00408-009-9165-3
McNally E, Ross C, Gleeson LE. The tuberculous pleural effusion. Breathe 2023;19:230142. DOI: https://doi.org/10.1183/20734735.0143-2023
Malhotra P, Aggarwal AN, Agarwal R, et al. Clinical characteristics and outcomes of empyema thoracis in 117 patients: a comparative analysis of tuberculous vs. non-tuberculous aetiologies. Respir Med 2007;101:423-30. DOI: https://doi.org/10.1016/j.rmed.2006.07.016
Usman F, Sayed TM, Maqsood A, et al. Investigation of the clinical characteristics of empyema thoracis patients at tertiary care facility. Pakistan J Chest Med 2022;28:478-83.
Ghazal S, Kumar A, Idrees N, et al. Role of Abram's pleural biopsy in determining the cause of empyema thoracis. Eur Respir J 2014:40.
Tousheed SZ, Ranganatha R, Kumar H, et al. Yield of pleural biopsy in different types of tubercular effusions. Indian J Tuberc 2020;67:523-7. DOI: https://doi.org/10.1016/j.ijtb.2020.07.023
Sardar K, Javed N, Safdar SS. Diagnostic yield of abrams pleural biopsy in patients presenting with lymphocytic exudative pleural effusion. Professional Med J 2019;26:1014-9. DOI: https://doi.org/10.29309/TPMJ/2019.26.07.1389
Ihsanullah KN, Jadoon H, Zaman M, Ahmed A. Yield of Abrams needle pleural biopsy in exudative pleural effusion. J Ayub Med Coll Abbottabad 2009;21:116-8.
Shaw JA, Diacon AH, Koegelenberg CF. Tuberculous pleural effusion. Respirology. 2019;24:962-71. DOI: https://doi.org/10.1111/resp.13673
Kohli M, Schiller I, Dendukuri N, et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database Syst Rev 2018;8:CD012768. DOI: https://doi.org/10.1002/14651858.CD012768
Sumalani KK, Akhter N, Chawla D, Rizvi NA. Utility of pleural fluid protein to differentiate malignancy from tuberculosis. J of Ayub Med Coll Abbottabad 2025;37:73-6. DOI: https://doi.org/10.55519/JAMC-01-12888
Kamal YA, Elkhayat H. Pleural tuberculosis. Thorac Surg Clin 2026;36:305-14. DOI: https://doi.org/10.1016/j.thorsurg.2026.02.008
Ethics Approval
How to Cite

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.